The 2026 American Diabetes Association Scientific Sessions wrapped this week in New Orleans after four days that brought together more than 12,000 clinicians, researchers, and healthcare professionals. The headline for every pharmacist managing a diabetes patient panel is this: with 565 individual recommendations embedded in the 2026 ADA Standards of Care, no single provider can realistically address them all. That reality is opening one of the most significant clinical opportunities the pharmacy profession has seen in diabetes management.
The ADA Itself Says Pharmacists Are Essential
The 2026 Standards formally elevate cardiovascular and kidney risk reduction to a co-primary treatment goal, meaning pharmacists should no longer treat A1C as the sole measure of therapeutic success in patients with type 2 diabetes. GLP-1 receptor agonists and SGLT2 inhibitors are now positioned as core cardiorenal protective therapies irrespective of A1C, and pharmacists play a critical role in helping patients understand that these agents offer long-term risk modification beyond blood sugar control.
The interprofessional framing in the 2026 Standards is explicit. No single clinician working in 15-minute appointment slots manages 565 recommendations across glucose control, cardiovascular risk, kidney protection, blood pressure, nutrition, mental health, social determinants, technology, and medication adherence. The ADA Standards acknowledge this directly, calling for coordinated interprofessional teams, including physicians, diabetes educators, dietitians, pharmacists, and mental health counselors, as the realistic delivery model for comprehensive diabetes care.
The pharmacist managing a patient panel of 200 diabetes patients is already the most consistent clinical touchpoint many of those patients have. The 2026 Standards give that touchpoint a 565-recommendation mandate.
The Clinical Inertia Problem That New Data Says Pharmacists Can Solve
Despite the availability of effective therapies and evidence-based guidelines, clinical inertia remains a major obstacle to optimal management of type 2 diabetes. Emerging data presented at the 2026 ADA Scientific Sessions highlight real-world barriers pharmacists encounter when supporting treatment intensification and suggest that targeted continuing education programs may improve pharmacists’ confidence and competence in addressing therapeutic delays. The researchers characterized barriers contributing to clinical inertia and evaluated the impact of a targeted CE program on pharmacist confidence and competence.
The ADA 2026 findings indicate that pharmacists recognize numerous real-world barriers to treatment intensification, with patient-related factors and access challenges emerging as the most common contributors to clinical inertia. Most critically, the data demonstrated that targeted educational interventions may improve pharmacists’ confidence and competence in identifying and addressing these barriers. Participants reported intentions to implement earlier guideline-directed therapy use and pharmacist-led approaches to support timely treatment escalation.
Clinical inertia is the specific failure mode where a patient’s A1C signals the need for therapy intensification, and nobody acts on it. The prescriber is busy. The patient doesn’t follow up. Months pass, then years. The patient deteriorates along a trajectory that evidence-based therapy could have prevented.
The pharmacist reviewing that patient’s refill history, monitoring their CGM data, and maintaining a monthly touchpoint is the clinician most positioned to catch the inertia and address it. The ADA session data confirms that when pharmacists are educated and empowered to act on these signals, they do.
The Guideline Changes Every Pharmacist Needs to Know This Week
Cardiorenal risk reduction is now a primary goal, not a secondary one
The most meaningful evolution in the 2026 ADA guidance is the repositioning of cardiovascular and kidney risk reduction as coequal priorities alongside glucose lowering. GLP-1 receptor agonists have taken on a more prominent role, supported by clinical trial evidence demonstrating benefit in patients with chronic kidney disease and those with heart failure with an ejection fraction of 40% or greater. Finerenone, a non-steroidal mineralocorticoid antagonist, also received recognition for its favorable heart failure outcomes in patients with diabetes.
This reframing matters for every MTM conversation a pharmacist has with a diabetes patient. Patients often understand GLP-1 therapy as a diabetes medication or a weight loss drug. The 2026 Standards say it is a kidney-protective, heart-protective, liver-protective cardiometabolic therapy that happens to lower blood sugar. That reframe changes adherence conversations, prior authorization justifications, and patient motivation all at once.
The blood pressure target just tightened for high-risk patients
Recommendation 10.4 was updated to state that a systolic blood pressure goal below 120 mmHg should be encouraged in individuals with high cardiovascular or kidney risk. This is supported by the BPROAD trial, which randomized individuals with diabetes and elevated CVD risk to an intensive systolic blood pressure goal below 120 mmHg and noted a 21% reduction in nonfatal stroke, nonfatal MI, heart failure, or cardiovascular death compared with standard management targeting below 140 mmHg.
Blood pressure goals for high-risk patients in 2026 now include below 120 mmHg systolic for those with high cardiovascular or kidney risk, below 130/80 mmHg for older adults when safe, and below 140/90 mmHg for individuals with poor health or limited life expectancy.
For the pharmacist managing a diabetes patient on three antihypertensives with a most recent blood pressure of 128/76, the 2026 Standards now suggest that target is still above goal for a high-risk patient. That is a conversation to initiate with the prescriber this week, not at the next quarterly visit.
CGM is now recommended at diabetes onset for everyone
The 2026 edition broadens continuous glucose monitoring eligibility to include all individuals on insulin or non-insulin therapies where CGM aids management. Additionally, automated insulin delivery system prerequisites for initiation have been removed to streamline technology access. Figure 9.5 was revised to suggest considering CGM for individuals with type 2 diabetes on basal insulin.
The pharmacist who builds a CGM onboarding program for newly diagnosed type 2 diabetes patients is now operating directly within ADA-recommended standard of care, not as a value-add. CGM counseling, device selection, data interpretation, and follow-up are pharmacist-deliverable services with established clinical impact and, increasingly, billable pathways.
New guidance for specific comorbidity combinations pharmacists see daily
Figure 9.4 was revised to include a dual GIP and GLP-1 receptor agonist or GLP-1 receptor agonist for glycemic management for those with type 2 diabetes, symptomatic HFpEF, MASLD or MASH, and obesity. SGLT2 inhibitor use guidance was clarified for individuals with CKD not on dialysis to reduce progression and cardiovascular risk. New guidance also addresses initiation or continuation of GLP-1 therapy in individuals on dialysis to reduce cardiovascular risk.
The MASLD connection to GLP-1 therapy covered in a prior issue of this newsletter is now embedded in the ADA pharmacologic guidance figure. The patient with type 2 diabetes, obesity, and elevated liver enzymes on semaglutide is receiving guideline-concordant therapy for three simultaneous conditions. The pharmacist who understands all three intersections, and communicates that to the patient, delivers a clinical service no other provider in that patient’s life has offered.
The Pharmacist Led Group Data That Came Out of New Orleans
Beyond the guideline updates, two specific pharmacist-led clinical programs presented data at the ADA 2026 sessions.
New data from the Safer Aging with Diabetes Monitoring trial presented at ADA 2026 showed that pairing continuous glucose monitoring with pharmacist-led group education sessions may meaningfully shift how high-risk older patients understand and manage glucose levels. The trial enrolled insulin-using adults with type 2 diabetes aged 75 years and older, initiating CGM and pairing it with two virtual, pharmacist-led group sessions held one month apart, structured around reviewing and discussing CGM-identified hypoglycemia events. Thematic analysis revealed four overarching themes illustrating how participants’ thinking and behavior evolved across the intervention, with meaningful improvements in hypoglycemia recognition, self-management confidence, and behavioral response to CGM data.
A pharmacist-led group session. Two virtual sessions, one month apart. Measurable cognitive and behavioral change in a population, adults 75 and older on insulin, that is among the highest-risk groups for hypoglycemia-related hospitalization, falls, and cognitive decline. This model is replicable in any pharmacy with a CGM-capable patient panel, a videoconferencing tool, and a pharmacist willing to facilitate a group conversation.
Reframing the MTM Conversation Using 2026 Language
Pharmacists should reframe medication therapy management conversations around cardiorenal protection rather than glucose control alone, emphasizing that SGLT2 inhibitors and GLP-1 receptor agonists are indicated for their cardiovascular and renal benefits even when A1C is at goal.
That single reframe changes the stakes of every MTM encounter with a diabetes patient who has comorbid heart failure, CKD, MASLD, or obesity. The question is no longer “Is the A1C at goal?” The question is “Has this patient received the therapies with proven cardiorenal benefit, and do they understand why those therapies matter for their survival, not just their blood sugar?”
Pharmacists who lead with that language in patient encounters align with the most current evidence-based guideline framing in the profession. Prescribers who haven’t updated their practice to the 2026 standards will find the pharmacist’s MTM note to be a more current clinical document than their own prescription pad.
Your Action This Week
Download the 2026 ADA Standards of Care summary at professional.diabetes.org. It is free and comprehensive. Review the Summary of Revisions document, a concise 10-page overview of what changed from 2025 to 2026.
Then identify the 10 recommendations most relevant to your patient population. If your panel skews toward older adults on insulin, the CGM and hypoglycemia prevention data from the SAGE trial belongs at the top of your list. If you manage primarily type 2 diabetes patients with cardiovascular risk, the cardiorenal repositioning and the new blood pressure target are your clinical priorities. If you manage patients with obesity and MASLD alongside diabetes, the updated GLP-1 guidance figure is your new counseling foundation.
The physician managing that same patient panel does not have time to implement 565 recommendations one patient at a time. The pharmacist who sees that patient monthly, reviews their CGM data, monitors their blood pressure trends, and coordinates their cardiorenal medication optimization has the time, the access, and now the guideline mandate to do exactly that.
That is the clinical identity of the pharmacist of 2030, and it is being built in diabetes management right now.
Sources: Pharmacy Times (ADA 2026: Pharmacist CE Programs May Reduce Clinical Inertia in Type 2 Diabetes, June 2026), Pharmacy Times (ADA 2026: The 2026 ADA Standards, A Pharmacist’s Guide to Cardiorenal Risk Reduction, June 2026), Pharmacy Times (ADA 2026: Clinical Pharmacist-Led Group Sessions Show Promise for Hypoglycemia Prevention in Older Adults, June 2026), ADA Diabetes Care Journal (Summary of Revisions: Standards of Care in Diabetes, 2026), ADA Diabetes Care Journal (Section 10: Cardiovascular Disease and Risk Management, 2026), AJMC (What Managed Care Should Watch at ADA 2026 Scientific Sessions, June 2026), MDPI (Paradigm Shifts in Diabetes Management: Key Highlights from the 2026 ADA Standards of Care), DiabetesontheNet (The 2026 ADA Standards of Care: What’s New?), TouchCARDIO (ADA 2026 Standards of Care: What the Update Means for Cardiovascular Clinical Practice), Cardi-OH Current (Key Updates from the 2026 ADA Standards of Care), Guideline Central (2026 ADA Standards of Care Summary)
